Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Panzyga, is an immunoglobulin presented as a 10% solution for intravenous use. It treats primary immunodeficiency diseases and provides antibody replacement in patients with insufficient immune response. GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Panzyga is used in the management of immune‑mediated conditions that require antibody replacement therapy.

- Primary immunodeficiency diseases: restores deficient IgG levels and reduces infection frequency. - Secondary immunodeficiency (e.g., chronic lymphocytic leukemia): provides passive immunity to lower infection risk. - Post‑exposure prophylaxis for certain viral infections: supplies neutralising antibodies to aid viral clearance. - Immunomodulation in autoimmune neuropathies: helps modulate immune activity and may improve neurological symptoms.

Panzyga may exhibit a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache - Fever - Chills - Nausea - Fatigue - Injection site discomfort

Serious or Rare Side Effects: - Anaphylaxis - Thromboembolic events - Acute renal failure - Hemolytic anemia - Severe aseptic aseptic meningitis - Transfusion‑trans 

Panzyga         …   g   g  t  t  t.

-   g  t

t \